Company Overview of Breckenridge Pharmaceutical, Inc.
Breckenridge Pharmaceutical, Inc. researches, develops, and markets generic prescription products in various therapeutic categories. The company markets its products in various dosage forms, including tablets, capsules, soft gel capsules, liquids, suspensions, and powders. It also provides various medical foods for the dietary management of patients with therapeutic or chronic medical needs; and prenatal and dietary supplements. In addition, the company handles various aspects of business operations, including procurement, purchasing, inventory management, warehousing, distribution, transportation, and customer service support. It serves chains, managed care customers, wholesalers, and distr...
6111 Broken Sound Parkway NW
Boca Raton, FL 33487
Founded in 1983
Key Executives for Breckenridge Pharmaceutical, Inc.
Senior Vice President of Sales for New Jersey Office
Vice President of Finance for CT Office
Associate Director of Technical Services for CT Office
Compensation as of Fiscal Year 2014.
Breckenridge Pharmaceutical, Inc. Key Developments
Breckenridge Pharmaceutical, Inc. Announces Approval for Repaglinide Tablets, USP
Apr 29 15
Breckenridge Pharmaceutical, Inc. announced the final approval by the U.S. Food and Drug Administration of the Abbreviated New Drug Application for Repaglinide Tablets USP, which is being manufactured and supplied by Standard Chem. & Pharm. Co. Ltd. Taiwan, and will be available in 0.5mg, 1mg, and 2mg strengths. Repaglinide Tablets are AB rated to Prandin®, which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The product launch plans are being finalized and first shipment will occur shortly.
Breckenridge Pharmaceutical, Inc. Announces Paragraph IV ANDA Litigation with Boehringer Ingelheim for its ANDA Dabigatran Etexilate Mesylate Capsules
Mar 12 15
Breckenridge Pharmaceutical, Inc. announced that it has filed an ANDA with a Paragraph IV certification for dabigatran etexilate mesylate capsules EQ 75 mg and EQ 150 mg strengths, a generic version of Pradaxa® by Boehringer Ingelheim. On March 5, 2015, Boehringer Ingelheim filed a Paragraph IV lawsuit against Breckenridge in the United States District Court for the District of New Jersey. Breckenridge filed its Paragraph IV ANDA on the first-possible submission date and expects to be entitled to 180-day exclusivity. Pradaxa® is a prescription drug that is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Breckenridge Pharmaceutical, Inc. Announces Paragraph IV ANDA Litigation with Sanofi for ANDA Cabazitaxel Solution; IV (infusion)
Feb 11 15
Breckenridge Pharmaceutical, Inc. announced that it has filed an ANDA with a Paragraph IV certification for cabazitaxel solution; IV (infusion) in 60 mg/1.5 mL (40 mg/mL) strength, a generic version of Jevtana by Sanofi. On January 14, 2015, Sanofi filed a Paragraph IV lawsuit against Breckenridge in the United States District Court for the District of New Jersey. Breckenridge filed its Paragraph IV ANDA on the first-possible submission date and expects to be entitled to 180-day exclusivity. The ANDA was developed and will be manufactured by Breckenridge's partner, Natco Pharma Limited. Jevtana is a prescription drug that is indicated to treat prostate cancer.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|